Morgan Stanley Inhibrx, Inc. Transaction History

Morgan Stanley

$1.27 Trillion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 17, 2024	BUY	$32.76 - $39.56 $18 Million - $21.7 Million	549,469 New	549,469 $19.2 Million
Q1 2024 Aug 16, 2024	BUY	$32.76 - $39.56 $8.27 Million - $9.99 Million	252,550 Added 85.06%	549,469 $19.2 Million
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $8.27 Million - $9.99 Million	252,550 Added 85.06%	549,469 $19.2 Million
Q4 2023 Aug 16, 2024	BUY	$14.5 - $38.0 $4.31 Million - $11.3 Million	296,919 New	296,919 $11.3 Million
Q4 2023 Feb 13, 2024	SELL	$14.5 - $38.0 $1.24 Million - $3.26 Million	-85,851 Reduced 22.43%	296,919 $11.3 Million
Q3 2023 Nov 15, 2023	SELL	$15.75 - $26.31 $29,688 - $49,594	-1,885 Reduced 0.49%	382,770 $7.02 Million
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $143,057 - $234,661	8,435 Added 2.24%	384,655 $9.99 Million
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $2.2 Million - $3.24 Million	119,202 Added 46.38%	376,220 $7.1 Million
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $1.94 Million - $3.2 Million	95,985 Added 59.61%	257,018 $6.33 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $239,497 - $511,465	20,682 Added 14.74%	161,033 $2.89 Million
Q2 2022 Oct 27, 2022	SELL	$8.52 - $25.26 $1.23 Million - $3.64 Million	-144,068 Reduced 50.65%	140,351 $1.59 Million
Q2 2022 Aug 15, 2022	SELL	$8.52 - $25.26 $1.23 Million - $3.64 Million	-144,068 Reduced 50.65%	140,351 $1.59 Million
Q1 2022 Oct 27, 2022	BUY	$19.89 - $43.18 $2.87 Million - $6.22 Million	144,068 Added 102.65%	284,419 $6.34 Million
Q1 2022 May 13, 2022	BUY	$19.89 - $43.18 $4.54 Million - $9.85 Million	228,052 Added 404.58%	284,419 $6.34 Million
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $1.42 Million - $2.44 Million	53,099 Added 1624.82%	56,367 $2.46 Million
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $82,288 - $123,563	3,268 New	3,268 $108,000

Others Institutions Holding INBX

# of Institutions

Shares Held

25.3K

Call Options Held

Put Options Held

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account